/
Cuprina Holdings Ltd. is a biomedical and biotechnology company focused on advanced wound care and cosmeceutical products. Headquartered in Singapore and founded in 2019, the company specializes in nature-based bioactive medical devices designed to manage and support healing of chronic wounds. Its flagship MEDIFLY line consists of medical-grade bio-dressing products made from sterile blowfly larvae, used as a biological debridement tool in maggot debridement therapy to remove non-viable tissue and promote wound bed preparation. Cuprina Holdings serves healthcare providers managing complex conditions such as diabetic foot ulcers, pressure injuries, and other hard-to-heal wounds, primarily in Asian markets including Singapore and Hong Kong. In addition to wound care, the company operates in the health and beauty segment, offering cosmeceutical products that apply its biomedical research and natural-materials expertise to skin-focused applications. Positioned within the medical instruments and supplies industry, Cuprina Holdings contributes a specialized, sustainable approach to chronic wound management and related skin health solutions.
$3.97
$0.04 (-1.00%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-9154.62% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 3.3%, steady but not accelerating. Margins contracted 6092.9pp, which offsets some of the top-line progress.
Negative free cash flow of -SGD 9M. The business is consuming cash, not generating it. Operating margin contracted 6092.9pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
SGD 50K
▲ +3.3% YoY
Net Income (TTM)
-SGD 5M
▼ -199.5% YoY
Op. Margin
-9154.62%
▼ -6092.9pp YoY
ROIC
-124.58%
▲ +496.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-SGD 9M
▼ -630.8% YoY
Op. Cash Flow (TTM)
-SGD 9M
▼ -635.5% YoY
Net Debt
-SGD 3M
Net Cash Position
Cash & Equiv.
SGD 3M
3Y CAGR: -4.1%
Continue Research
Cuprina Holdings (CUPR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cuprina Holdings scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Cuprina Holdings scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -9,154.6% operating margin and a -124.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CUPR's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.